ADCs | pharmaphorum

Friday 28 August 2026

ADCs

News

ADC linker in action to cancer cell

Akeso and CStone secure China clearances for next-generation...

Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, with Tony Jarkowski

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

News

EC building flags

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

Oncology

How antibody-drug conjugates became oncology's hottest therapeutic class

How antibody-drug conjugates became oncology's hottest thera...

Oncology

Daiichi Sankyo gears up for five ADC launches in 2026

Daiichi Sankyo gears up for five ADC launches in 2026

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.